Home » Stocks » CRBP

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Stock Price: $1.66 USD -0.06 (-3.49%)
Updated Apr 19, 2021 3:22 PM EDT - Market open
Market Cap 215.06M
Revenue (ttm) 3.94M
Net Income (ttm) -111.27M
Shares Out 78.13M
EPS (ttm) -1.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $1.66
Previous Close $1.72
Change ($) -0.06
Change (%) -3.49%
Day's Open 1.68
Day's Range 1.63 - 1.80
Day's Volume 4,019,830
52-Week Range 0.91 - 9.78

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will conti...

Other stocks mentioned: GNLN, HUGE, IIPR, NTEC, OGI
2 weeks ago - Schaeffers Research

Norwood, MA, March 30, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medi...

2 weeks ago - GlobeNewsWire

Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 month ago - Zacks Investment Research

Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) moved higher by 5.2% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 75.61% year over year to ($0...

1 month ago - Benzinga

As usual, no earnings reports are scheduled for release on Friday afternoon. And with just two weeks to go in the first calendar quarter of 2021, there are only two earnings reports that we think are wo...

1 month ago - 24/7 Wall Street

Norwood, MA, March 09, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medi...

1 month ago - GlobeNewsWire

•   Company to host conference call and webcast on Monday, March 15, 2021 at 8:30 a.m. ET

1 month ago - GlobeNewsWire

Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

If January and February are a sign of things to come in 2021, traders and investors are going to make a lot of money this year. 4 hot small cap stocks on the move are Corbus Pharmaceuticals (NASDAQ: CRB...

Other stocks mentioned: MJNA, MVIS, REZZF
2 months ago - OTC PR Wire

Inside the top performing stocks in the top ETF of January.

Other stocks mentioned: APHA, CGC, HEXO, POTX, TLRY
2 months ago - Zacks Investment Research

Major disappointment last year due to lenabasum not meeting its endpoints in a phase 3 and phase 2 trial. Massive expectation meant that the company had to downsize significantly to keep operations going.

2 months ago - Seeking Alpha

Norwood, MA, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medic...

2 months ago - GlobeNewsWire

Corbus Pharmaceuticals (CRBP) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

3 months ago - Zacks Investment Research

Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

Investors need to pay close attention to Corbus (CRBP) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

Corbus Pharma (CRBP) is seeing massive gains for CRBP stock on Tuesday despite a lack of recent news from the pharmaceuticals company. The post Corbus Pharma: 8 Things for CRBP Stock Investors to Know A...

4 months ago - InvestorPlace

Norwood, MA, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medic...

5 months ago - GlobeNewsWire

Corbus Pharmaceuticals Holdings, Inc. (CRBP) CEO Yuval Cohen on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Corbus Pharmaceuticals Holdings, Inc.'s (CRBP) CEO Yuval Cohen On Q3 2020 Results - Quick Version Earnings Call Transcript

5 months ago - Seeking Alpha

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -4.88% and -64.01%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) decreased 1.6% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 34.37% year over year to ($0.43), whi...

5 months ago - Benzinga

Norwood, MA, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medic...

5 months ago - GlobeNewsWire

On Tuesday, November 10, Corbus Pharmaceuticals (NASDAQ: CRBP) will release its latest earnings report. Benzinga's outlook for Corbus Pharmaceuticals is included in the following report.

5 months ago - Benzinga

Norwood, MA, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medic...

5 months ago - GlobeNewsWire

Norwood, MA, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medic...

5 months ago - GlobeNewsWire

Corbus Pharmaceuticals (CRBP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Norwood, MA, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medic...

5 months ago - GlobeNewsWire

Norwood, MA, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medic...

5 months ago - GlobeNewsWire

Norwood, MA, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medic...

6 months ago - GlobeNewsWire

Corbus (CRBP) releases disappointing top-line results from its 28-week phase IIb study of lenabasum in patients with cystic fibrosis.

6 months ago - Zacks Investment Research

Norwood, MA, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medic...

6 months ago - GlobeNewsWire

Investors need to pay close attention to Corbus (CRBP) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) shares were plummeting hard Tuesday following an adverse clinical data readout.

7 months ago - Benzinga

A late-stage clinical failure is weighing heavily on the biotech's stock today.

7 months ago - The Motley Fool

Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) has reported that its systemic sclerosis study failed to reach the endpoints, and investors were not pleased.

7 months ago - 24/7 Wall Street

Norwood, MA, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative me...

7 months ago - GlobeNewsWire

Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

Corbus Pharmaceuticals Holdings, Inc. (CRBP) CEO Yuval Cohen on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Norwood, MA, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative med...

8 months ago - GlobeNewsWire

Norwood, MA, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative med...

8 months ago - GlobeNewsWire

Norwood, MA, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative med...

8 months ago - GlobeNewsWire

Norwood, MA, July 30, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative med...

8 months ago - GlobeNewsWire

Norwood, MA, July 29, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative med...

8 months ago - GlobeNewsWire

After 6 Years Corbus Shareholders Face The Ultimate Milestone: The Imminent Release Of Lenabasum's Phase 3 Data

8 months ago - Seeking Alpha

Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.

8 months ago - Zacks Investment Research

What’s the choice between these U.K and U.S. biotech-cannabis companies?

Other stocks mentioned: GWPH
9 months ago - The Motley Fool

Norwood, MA, July 08, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative med...

9 months ago - GlobeNewsWire

Norwood, MA, June 29, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative med...

9 months ago - GlobeNewsWire

Norwood, MA, June 22, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative med...

9 months ago - GlobeNewsWire

About CRBP

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. Its lead product candidate is lenabasum, a cannabinoid receptor type 2 (CB2) that is in Phase III clinical trial for the treatment of dermatomyositis; and in Phase II clinical trial to treat systemic lupus erythematosus. The company is also developing cannabinoid receptor type 1 inverse agonist program for... [Read more...]

Industry
Biotechnology
Founded
2009
CEO
Yuval Cohen
Employees
76
Stock Exchange
NASDAQ
Ticker Symbol
CRBP
Full Company Profile

Financial Performance

In 2020, CRBP's revenue was $3.94 million, a decrease of -89.11% compared to the previous year's $36.14 million. Losses were -$111.27 million, 55.7% more than in 2019.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for CRBP stock is "Hold." The 12-month stock price forecast is 2.23, which is an increase of 34.34% from the latest price.

Price Target
$2.23
(34.34% upside)
Analyst Consensus: Hold